177Lu-RM2 (177Lu-BAY-1017858) is a molecule corresponding to a different than PSMA biological approach for treating prostate cancer developed originally at Bayer. Unfortunately, it does not seem this molecule is presently supported by a private group, but some research was reactivated in 2020.
177Lu-RM2 efficiently targets the BB2r (Bombesin receptor 2) expressed on CRPC cells in vivo. This molecule is associated to the diagnostic agent 68Ga-Bombesin (68Ga-RM2).
Leading Emitter: beta electrons (β–)